CADASIL Association

P.O. Box 124

Helmetta, NJ 08828

Phone messages: 307-215-9840

CADASIL Association

P.O. Box 124

Helmetta, NJ 08828

Phone messages: 307-215-9840


P.O. Box 124

Helmetta, NJ 08828

Phone messages: 307-215-9840

Dr. Joseph Arboleda-Velasquez, M.D., Ph.D.

Assistant Professor, Harvard Medical School, Cambridge, Massachusetts


Dr. Arboleda-Velasquez’s Current Research Project:

“Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is a frequent cause of stroke and cognitive decline in adult individuals with a family history of these conditions. CADASIL is caused by mutations in a gene called Notch 3. The Notch 3 gene is part of a group of genes that help cells communicate with each other. Cells use these social cues from neighboring cells as useful information to make decisions regarding their fate. However, it is not clear how Notch 3 mutations lead to cell-cell miscommunication and how this leads to stroke. In my research, I use mouse models of CADASIL and culture cells derived from these animals to study how CADASIL mutations affect Notch 3 function and how normal physiology could be restored using genetic manipulations and newly developed drugs. This work may lead to the identification of novel therapeutic targets for CADASIL as many drugs that modulate Notch signaling are currently under development for other human conditions.”


Dr. Arboleda-Velasquez, or "Joe" as he prefers to be called, has a question and answer page in Embrace, the newsletter of cureCADASIL.


Joe was the Scientific Director for the 2013 Boston CADASIL Family Conference hosted by cureCADASIL Association June 27-29, 2013.



Dr. Angelo M. Santiago, M.D.

Neurologist & Owner at Central Wyoming Neurology, Casper, Wyoming  


Trustee Janet Mills credits Dr. Santiago with getting her a correct diagnosis of CADASIL, and for the compassionate manner in which he deals with his patients. Dr. Santiago's expertise is in epilepsy, and many others of his patients have MS/Multiple Sclerosis. He continues to expand his knowledge of CADASIL and other neurological conditions.




Michelle A. McGuinness, M.S., RAC

Regulatory Affairs, Quality & Compliance Leader, Greater Philadelphia Area


Michelle Mc Guinness is a biopharmaceutical leader with expertise in the quality, regulatory and compliance aspects of pharmaceutical manufacturing & marketing. Ms. McGuinness earned a bachelor's degree in biology/biotechnology from Kean University and a master's degree in Quality Assurance & Regulatory Affairs from Temple University School of Pharmacy. She is a member of the Regulatory Affairs Professional Society and the American Society for Quality. Ms. Mc Guinness proudly volunteers for the CADASIL Association and the Southeastern PA chapter of HDSA.


Ms. Mc Guinness has a passion for rare disease advocacy and awareness. She understands the scientific aspects of CADASIL as well as the impact that a rare disease has on a family. While Ms. Mc Guinness was in high school, her father suffered his first stroke. At the time doctors uncovered that her dad had a variety of risk factors for stroke: high cholesterol, high blood pressure, cigarette smoking, poor diet, etc. A variety of medicines were prescribed to address the risk medical factors, but the strokes and TIAs continued. 15+ years after Ms. Mc Guinness's father had his first stroke, another family member was diagnosed with CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopthy). We now know that Ms. Mc Guinness's father had CADASIL. Ms. Mc Guinness is committed to advocacy, awareness & finding a cure for CADASIL.


CADASIL Association

P.O. Box 124

Helmetta, NJ 08828

Phone messages: 307-215-9840


Dr. Jennifer Majersik, M.D., M.S.

Chief, Division of Vascular Neurology, University of Utah Hospital, Salt Lake City, Utah


Dr. Majersik established her vascular neurology practice within the Stroke Center at the University of Utah in 2008. Her clinical practice includes evaluating and treating acute strokes in the hospital and emergency department, managing patients on the inpatient general neurology service, and providing outpatient consultation in the stroke clinic, including urgent referrals.


She has a particular interest in rare single gene disorders causing stroke (such as CADASIL), hypercoaguable states (such as Antiphospholipid Antibody Syndrome), and vascular malformations (such as cavernous malformations and hereditary hemorrhagic telangiectasias). She also provides emergency consultation to stroke patients at community hospitals via the telestroke network.


In 2010, she became Director of the University of Utah Stroke Center in addition to her position as Fellowship Director. Dr. Majersik is currently studying the genetic underpinnings of stroke in large families in Utah and more common polygenetic disorders leading to increased risk of stroke.



Dr. Swati Sathe, M.D., M.S.

Rutgers New Jersey Medical School 


Dr. Sathe was previously the Chief of the Division of Neurology at St. Joseph's Regional Medical Center in Paterson, New Jersey. She was also previously the Assistant Professor of Neurology in the Neurogenetics Division at New York University. She received her medical training at the University of Mumbai and New York University. She has authored several journal articles. Dr. Sathe planned and organized the first ever USA CADASIL Symposium on July 30, 2010 in DeKalb, Illinois with the United Leukodystrophy Foundation.



cureCADASIL Association


10 Schalks Crossing Road


Suite 501A-133


Plainsboro, NJ  08536



Phone messages: 307-215-9840

Dr. Chirag S. Shukla, M.D.

Capital Institute for Neurosciences


Clinical Neurophysiology

Electrodiagnostic Medicine


Vascular Neurology

Dr. G. Peter Gliebus, M.D.

Director, Alzheimer's Disease and Cognitive Disorders Program

Capital Institute for Neurosciences


A board certified neurologist, Dr. Gliebus received his medical degree from Vilnius University and specializes in cognitive disorders.  Following an internal medicine residency at Atlanticare Regional Medical Center, Dr. Gliebus completed a neurology residency at Drexel University College of Medicine where he was named chief resident. Dr. Gliebus was then named as the J. Rosenstone Behavioral and Cognitive Neurology Fellow at Northwestern University's Feinberg School of Medicine's Cognitive Neurology and Alzheimer's Disease Center.


















Dr. Michael Wang, M.D, Ph.D.

University of Michigan Health System


Dr. Wang is a clinician scientist at the University of Michigan and the VA Ann Arbor Healthcare System. He cares for patients with CADASIL at both of these centers and directs a laboratory which studies the molecular biology and pathology of CADASIL. The lab has been federally funded since 2003 with grants from the NIH and the VA.  At the University of Michigan, Dr. Wang is the Director of Molecular Stroke Research, and, at the Ann Arbor VA, he serves as the Chief of the Neurology Service.

His laboratory website is

Josef P. Bogdan, M.H.S.A., L.N.H.A.

Executive Director at Hamilton Continuing Care Center, Hamilton, NJ


Josef P. Bogdan is a healthcare professional with diverse experience in continuing care management. At Hamilton Contuining Care Center, he directs the operations of a 180 bed health care facility comprised of skilled nursing, sub-acute care, dementia care, and long-term care. He attended George Washington University in Washington, DC where he received his Master of Health Services Administration degree, with a concentration in health care systems.

Josef P. Bogdan's full resume


Dr. Irene Griswold-Penner, Ph.D.

Cofounder and CSO of Imago Pharmaceuticals, Inc.


Imago engages in preclinical and clinical development of stress-activated kinase, Jun N-terminal kinas (JNK) drug candidates implicated in neurodegenerative diseases, fibrosis and additional indications.


Dr. Griswold-Penner's background in therapeutic development for neurodegenerative diseases will contribute to cureCADASIL by providing expertise in developing biomarkers and therapies that could result in therapies to reduce disease prgression for CADASIL patients.

Irene Griswold-Penner's full bio

Dr. Artiom Gruzdev, Ph.D.


Dr. Gruzdev received his Ph.D. in Genetics and Molecular Biology from University of North Carolina at Chapel Hill. His research focus includes generating transgenic animals (mouse models) for the study of various diseases, iPSC technology, coordinating large scale human population studies focused on single nucleotide polymorphism (SNP) variants, and other aspects of molecular biology including its application to cardiovascular ischemia-reperfusion injury.